(2026). CtDNA levels after neoadjuvant therapy may predict breast cancer recurrence better than pathologic complete response. Pharma Business Week, N.PAG.
Chicago Style (17th ed.) Citation"CtDNA Levels After Neoadjuvant Therapy May Predict Breast Cancer Recurrence Better than Pathologic Complete Response." Pharma Business Week 2026: N.PAG.
MLA (9th ed.) Citation"CtDNA Levels After Neoadjuvant Therapy May Predict Breast Cancer Recurrence Better than Pathologic Complete Response." Pharma Business Week, 2026, p. N.PAG.
Warning: These citations may not always be 100% accurate.
